uniQure N.V.
No enriched coverage for $QURE in the last 7 days.
No SEC Form 4 filings for $QURE in the last 30 days.
See all $QURE insider activity →The article cites AI infrastructure demand evidence from SiTime, SanDisk, SpaceX, and Aeva and highlights Nebius Group N.V. (NBIS), which reported Q2 revenue of $582 million, up 454% YoY, with an annualized $3 billion run-rate and four AI-cloud contracts over $1 billion each, shares up 34% Wednesday. It also discusses uniQure N.V. (QURE) after FDA accelerated-approval pathway updates, including option-structure payoff ranges.
uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.
uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.
Recent QURE coverage spans earnings, financial news and regulation.
Regulatory-path reopening is a material catalyst that can re-rate probability-weighted outcomes for AMT-130, favoring long-vol or structured upside.
FDA-alignment and a planned Q3 2026 BLA submission are a near-term regulatory milestone that can re-rate probability-weighted timelines for AMT-130.
Positive early efficacy and ERT discontinuation are offset by ongoing protocol pause tied to dose-limiting, asymptomatic liver enzyme elevations.
For a biotech with binary regulatory risk, an upgrade that increases modeled success probability can materially shift sentiment.
FDA alignment on the AMT-130 accelerated-approval BLA pathway removes a key regulatory overhang, supporting near-term sentiment and risk reduction.
alphai scores every news story that mentions QURE with an AI model for sentiment and relevance, and aggregates insider trades from uniQure N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article cites AI infrastructure demand evidence from SiTime, SanDisk, SpaceX, and Aeva and highlights Nebius Group N.V. (NBIS), which reported Q2 revenue of $582 million, up 454% YoY, with an annualized $3 billion run-rate and four AI-cloud contracts over $1 billion each, shares up 34% Wednesday. It also discusses uniQure N.V. (QURE) after FDA accelerated-approval pathway updates, including option-structure payoff ranges.
7 min readuniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.
8 min readuniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.
5 min readAnalysts issued multiple rating changes. Humana (HUM) was upgraded by Leerink to Outperform with a $513 target and by Piper Sandler to Overweight with a $463 target. Bloom Energy (BE), Sprouts (SFM), uniQure (QURE), and Core Scientific (CORZ) also saw upgrades. Las Vegas Sands (LVS) was downgraded to Hold by Argus. Other actions included P&G (PG), SiteOne (SITE), Capricor (CAPR), and Fannie Mae (FNMA).
3 min readuniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.
6 min readuniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.
6 min readuniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline fo
6 min readReuters reports biotech experts and industry executives are urging the FDA to rebuild scientific expertise and update clinical-trial standards as it plans to hire about 2,200 employees, shorten trial timelines, and speed cell and gene therapy reviews. They cite recent FDA leadership turnover and concerns about political influence after resignations of Marty Makary and Vinay Prasad. Investors are watching.
6 min readThe article describes a volatile week driven by Strait of Hormuz tanker attacks and U.S. revocation of Iranian oil-sales waivers, pushing crude above $75, alongside chip and AI stock moves. It cites Samsung’s record Q2 operating profit estimate, SK Hynix’s $26.5B ADR offering priced at $149 and opening at $170, and reports on memory price hikes and Penguin Solutions’ revenue/guidance. It also lists multiple option and stock exits.
6 min readKapusta Matthew C (CEO, Managing Director) sold 21,082 shares of uniQure N.V. (QURE) at an average of $45.16 ($44.43–$45.89, $0.95M total) across 3 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
1 min read
